XEN-D0501
- Generic Name
- XEN-D0501
- Drug Type
- Small Molecule
- Background
XEN-D0501 is a tetrahydronaphthyl urea-based selective TRPV1 antagonist being investigated for the treatment of erythromelalgia.
A Trial Investigating the Effect of 4 Weeks Dosing of XEN-D0501 on Blood Glucose Reduction in Patients With Diabetes
Phase 2
Completed
- Conditions
- EfficacySafetyPharmacokineticsDiabetes Mellitus, Type 2
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Pila Pharma
- Target Recruit Count
- 54
- Registration Number
- NCT05353686
- Locations
- 🇱🇹
Kedainiai Hospital / Outpatient Department, Kedainiai, Lithuania
🇱🇹Karoliniskiu Outpatient Clinic, Vilnius, Lithuania
🇱🇹Kristavita, JSC, Jonava, Lithuania
A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With COPD
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-09-08
- Last Posted Date
- 2015-07-15
- Lead Sponsor
- Xention Ltd
- Target Recruit Count
- 27
- Registration Number
- NCT02233686
- Locations
- 🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom
A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With Chronic Idiopathic Cough
- First Posted Date
- 2014-09-08
- Last Posted Date
- 2015-07-15
- Lead Sponsor
- Xention Ltd
- Target Recruit Count
- 18
- Registration Number
- NCT02233699
- Locations
- 🇮🇪
Belfast City Hospital, Belfast, Ireland
🇬🇧University Hospital of South Manchester, Manchester, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath